Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
NCT01522872
Unknown
This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2016
Locations: Pacific Cancer Care, Monterey, California +9 locations
Conditions: Multiple Myeloma
Register for Updates
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
NCT02188173
Completed
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2016
Locations: Retinal Consultants of Phoenix, Phoenix, Arizona +17 locations
Conditions: Macular Edema
Register for Updates
Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery
NCT01450007
Completed
Pre-operative perineural injection of dexamethasone mixed with local anesthetic in peripheral nerve blockade for orthopedic surgery has been shown to prolong the length of analgesia, improve visual analog pain scores, decrease post-operative opioid use, and decrease post-operative nausea. No study has been published to determine if this effect is a result of systemic absorption of dexamethasone or is a local effect of the drug on neuronal activity at the injection site. This study is a prospecti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2016
Locations: Mayo Clinic in Arizona, Phoenix, Arizona
Conditions: Shoulder Injury
Register for Updates
Dexamethasone or Clonidine as Adjuncts to Ropivacaine for Caudal Analgesia on Analgesia Duration in Children
NCT02773602
Unknown
Comparing the duration of pain relief from caudal analgesia when adjuncts like dexamethasone, clonidine, or saline (salt water) are added to ropivacaine.
Gender:
ALL
Ages:
Between 6 months and 6 years
Trial Updated:
05/12/2016
Locations: Memorial Hermann Hospital, Houston, Texas
Conditions: Postoperative Pain
Register for Updates
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
NCT01807286
Terminated
The goal of this clinical research study is to find the highest tolerable dose of pomalidomide that can be given in combination with melphalan and dexamethasone that can be given to patients with AL amyloidosis. The safety of this drug combination will also be studied. Pomalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. This may decrease the growth of cancer cells. Melphalan is designed to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Myeloma
Register for Updates
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
NCT01204164
Completed
This is a multicenter, open-label, dose escalation Phase 1 study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2016
Locations: RMCC, Denver, Colorado +8 locations
Conditions: AML, ALL, Blast Crisis, MDS, Multiple Myeloma
Register for Updates
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
NCT00532155
Completed
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC). The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunog... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2016
Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey +31 locations
Conditions: Carcinoma, Non Small Cell Lung
Register for Updates
Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study
NCT01059955
Completed
This is an initial clinical trial evaluating whether different doses of iontophoresis for delivery of dexamethasone phosphate can be tolerated by eyes of patients with non-infections, non-necrotizing scleritis. A secondary goal is to get preliminary information about whether the treatment is likely to be an effective treatment for scleritis. If the results are favorable, further trials evaluating the treatment may be pursued. Funding sources: FDA OOPD, Eyegate Pharmaceuticals, Inc.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2016
Locations: University of California, San Francisco, San Francisco, California +5 locations
Conditions: Non-infectious, Non-necrotizing Anterior Scleritis
Register for Updates
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
NCT01499849
Completed
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving HEC. Rolapitant or placebo will be administered prior to initiation of chemotherapy on Day 1 with granisetron and dexamethasone. Subjects will record all events of emesis and use of rescue medication for established nausea and/or vomiting, and will indicate the severity of nausea they experienced in each of the previous 24 hours in the Nausea and Vomiting (NV) Sub... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2016
Locations: TESARO Inc, Waltham, Massachusetts
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):
NCT02027272
Terminated
This is a double blinded, placebo-controlled trial to determine if IV dexamethasone more quickly than placebo assists resolution of Posterior Reversible Encephalopathy Syndrome (PRES) encountered in eclamptic patients. All patients regardless of assignment to placebo or steroid will receive standard therapy to include magnesium sulfate, blood pressure medications and diuretics. We hypothesize that the addition of dexamethasone to standard therapy will accelerate CNS recovery more quickly than st... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/19/2016
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Eclampsia
Register for Updates
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
NCT01736917
Completed
The hypothesis is that the substitution of multi-day oral aprepitant with (intravenous) IV fosaprepitant, in combination with a 5-HT3 receptor antagonists (5HT3RA) + dexamethasone will provide comparable protection from 5 day cisplatin chemotherapy induced nausea and vomiting, compared to the results of our prior study of aprepitant. This study will be the first clinical trial evaluating fosaprepitant in patients receiving multi-day cisplatin. This will be a single arm, phase II study. The inves... Read More
Gender:
MALE
Ages:
15 years and above
Trial Updated:
04/18/2016
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana +3 locations
Conditions: Chemotherapy-Induced Nausea and Vomiting
Register for Updates
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
NCT00477971
Completed
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having an autologous stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given so that more plasma cells are killed. By reducing the number of plasma cells, the disease may progress more slowly. It is not yet known whether combin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2016
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates